1. Approval of Q2 FY26 Financial results 2. Upon recommendation of Audit committee, board approved to Invest by way of acquiring 100 % equity share capital of M/s Celliimune Biotech Private Limited. 3. Upon recommendation of Audit committee, board approved invest upto Rs. 10 Crores in Captive Hybrid Solar Power Project for Limbasi Plant by entering into an agreement with relevant party.
CONCORDBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Concord Biotech's Board approved three items: (1) the financial results for Q2 FY26, (2) the acquisition of 100% equity share capital of Celliimune Biotech Private Limited, recommended by the Audit Committee, and (3) an investment of up to Rs. 10 Crores in a captive hybrid solar power project for its Limbasi Plant. The acquisition adds a new entity under Concord Biotech, while the solar investment supports the company's sustainability and energy cost efforts at its manufacturing facility. No financial details of the acquisition (deal value, revenue, or valuation metrics) have been disclosed in this announcement.
Shareholders should watch for further disclosures on the acquisition rationale, cost, and synergy with Concord Biotech's existing business. The Rs. 10 Crore solar investment is modest relative to corporate size and signals operational focus on reducing energy costs. Short-term stock reaction will likely depend on Q2 FY26 results and acquisition valuation details when announced.